Elections to ISPE's board and a Roche exec joining Dendreon's board – People on the move
The 2009-2010 elections for ISPE's international board of directors has been completed, with 10 people being appointed.
Alan Mac Neice, Andre Walker, Arthur Perez, Charlotte Enghave Fruergaard, Damian Greene, Doyle Johnson, Andrzej Szarmanski, Morten Stenkilde and Antonio Buendia will now serve on the board of directors.
Dendreon has elected Ian Clark and Pedro Granadillo to its board of directors.
Clark is currently head of global product strategy and chief marketing officer at Roche, Pharma Division and will become head of Genentech's North American commercial operations in January.
Granadillo last served as senior vice president of global manufacturing and human resources at Eli Lilly and worked at the big pharma for more than 30 years.
Michael Buckley has joined Takeda San Francisco as vice president of process sciences.
Buckley will be responsible for directing materials supply to support research and prepare for production of therapeutic antibody candidates.
He has previously held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation and helped develop Bexxar, the first centrally manufactured radiopharmaceutical-Iodine-131 antibody.
Elite Pharmaceuticals has appointed Jerry Treppel as CEO and Ashok Nigalaye as chief scientific officer.
Treppel has more than 20 years experience as a a specialty pharmaceutical analyst and has served on Elite's Board of Directors since October 2008.
Since 2003 Treppel has served as the managing member of Wheaten Capital Management and has held analyst positions at companies inclduing Merrill Lynch & Co and Peabody & Co. Nigalaye has served as president and CEO of Epic Pharma since July 2008 and has also worked at Actavis Totowa.
